Creative Medical Technology Holdings Inc (CELZ)

$3.15 +0.33 (11.70%)
Market Cap 7.28M
Revenue (ttm) 10,000.00
Net Income (ttm) -5.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -54,900.00%
Debt to Equity Ratio 0.00
Volume 182,500
Avg Vol 91,900
Day's Range N/A - N/A
Shares Out 2.58M
Stochastic %K 75%
Beta 2.05
Analysts Sell
Price Target $20.00

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology
Sector: Healthcare
Phone: 480 399 2822
Address:
211 East Osborn Road, Phoenix, United States
wokazn
wokazn Nov. 14 at 5:46 AM
$CELZ clue #1🙂 Efficacious in FDA clinical trialđŸ”„ ImmCelzÂź Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients https://share.google/h0CAPW2DsVvsliL8u
1 · Reply
gteu3212
gteu3212 Nov. 11 at 3:22 PM
$CELZ $CELZ đŸ”„â€” Quietly Building a Multi-Billion Dollar Platform đŸ”„ Most traders only see the price. Serious investors look at positioning — and CELZ is positioning itself better than almost any microcap biotech out there. Here’s what the market is missing: ✅ Two FDA-cleared clinical programs running in parallel ✅ Cash runway of ~9M+ after the latest 10-Q ✅ Zero debt ✅ Lowest R&D burn I’ve seen for a company with this pipeline ✅ Early signals of safety + feasibility in ADAPT ✅ Type-1 Diabetes (CREATE-1) could dwarf everything ✅ New BioDefense program = potential access to federal funding ✅ Tiny float → any real news can hit like a bolt of lightning ⚡ When ADAPT delivers in 2026, it won’t just be “good news.” It will be the moment this entire platform becomes validated — and validation is the multiplier nobody is pricing in. Microcaps don’t move gradually. They move all at once
 and usually when people least expect it. #Biotech #CellTherapy #Undervalued
0 · Reply
Peterb3346
Peterb3346 Nov. 11 at 12:30 AM
$CELZ apparently this thing has hiccups. $CELZ can help if you have a stroke, but has problems with hiccups.
0 · Reply
JayGainsby
JayGainsby Nov. 10 at 3:17 PM
$CELZ The recent 10Q gave a good snap shot of CELZ’s warrant landscape and future dilution. Over the next year or two, CELZ’s share count will almost certainly double as the already-paid-for and low-priced warrants convert into stock. This dilution, however, is already priced in and already paid for. Cash today (pro forma) ≈ $9.1 M (Sept 30 balance + Oct net proceeds). If every warrant priced around today’s share level were exercised, CELZ would receive an additional $12 – 13 million in cash and issue about 3.9 million new shares. So, for the next stage of CELZ’s development float will most likely end up around 7.5 M OS with roughly $22 million cash to fund future clinical work. That float is still tiny and the cash runway is great. If science bears out, CELZ has all of the ingredients for huge break out. Bring on the clinical trial updates!
0 · Reply
wokazn
wokazn Nov. 10 at 3:16 PM
$CELZ another piece of the puzzle developing with Greenstone that will benifit Celz's recent BioDefense Inc. news, that was not mentioned. https://www.biopharmadive.com/press-release/20251023-greenstone-biosciences-and-illumina-announce-collaboration-to-advance-preci/
0 · Reply
BoilermakerB
BoilermakerB Nov. 10 at 12:56 PM
$CELZ 10Q out......same old same old, minimal revenue and not profitable yet. Expenses going up and still a long way to topline results on 2 possible products. Also the 10Q disclosed that when the patents are extended, they pay with shares, so dilution is guaranteed to progress as they move toward a actual product..... Long road ahead here....strap in.
2 · Reply
HODLnCaulfield
HODLnCaulfield Nov. 10 at 12:40 PM
$CELZ
0 · Reply
gteu3212
gteu3212 Nov. 10 at 10:46 AM
🚀 $CELZ — The Setup for a Massive 2026 Breakout 🚀 The new 10-Q paints a very clear picture: CELZ is financially stable, burning minimal cash, carrying zero debt, and holding ~$9M+ runway after the recent warrant funding. All clinical programs remain fully intact and moving forward. ✅ ADAPT (lower back pain) now entering the most important stage ✅ CREATE-1 (Type 1 Diabetes) in IND momentum ✅ BioDefense program opening the door to federal funding ✅ Cash burn extremely low for a biotech with TWO FDA-cleared trials ✅ Float still tiny ✅ No toxic financing This is the quiet phase before the storm. Q1/Q2 2026 = the moment we find out if the platform works in humans. If ADAPT hits, the entire ImmCelzℱ engine gets validated
 and that changes everything. 📈 With success: » $10–$18 becomes realistic » $20–$40 on strong efficacy » Multi-program validation = $50+ potential The fundamentals are stronger now than ever before! #CELZFamily #Biotech #RegenerativeMedicine #2026Catalyst
0 · Reply
JayGainsby
JayGainsby Nov. 8 at 12:35 AM
$CELZ Q3 10Q was released. Pros: -~$9.1M cash (~ 20–24 months at the current burn) -Further confirmation that CELZ-201 ADAPT trial looks safe. It’s nearly finished collecting data, and early signs are hopeful, but official results will not be out for a month or two
If efficacy on this treatment holds up (remaining trials/experiments should be affordable with current cash ~) -Lean ops. I'd love to hear about more early bios in stage 1/2 with promising results & $ to cover P3. If efficacy holds up, stock price should recalibrate (and there is a lot more potential in the pipeline/patent umbrella. Positive results/gains in any area would boost ALL of it. Cons OS is increasing. Dilution will likely X2 (at least) in the next ~yr (float will still be TINY & 201 ADAPT should be well on to P3 (or NOT) Warrants’ strike price was reset from 3.75 to $2.86- (not good and the reason for the resetting of the current floor). Clinical trial news remains the KEY factor
0 · Reply
JayGainsby
JayGainsby Nov. 6 at 3:44 PM
$CELZ We should be getting the 3rd Q 10Q shortly (before primary completion clinical trial data) According to Zack's report, "over the last 30 days, the consensus EPS estimate for the current year has increased 32.3%," which indicates some are expecting much better earnings (or losses in this case 🙂) than they predicted earlier. I am interested to see how actual burn/revenue relate to those forecasts and why?
0 · Reply
Latest News on CELZ
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Oct 30, 2025, 9:15 AM EDT - 15 days ago

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Oct 29, 2025, 9:00 AM EDT - 16 days ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Creative Medical Technology Holdings Issues Letter to Shareholders

Oct 27, 2025, 8:15 AM EDT - 18 days ago

Creative Medical Technology Holdings Issues Letter to Shareholders

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Oct 7, 2025, 9:15 AM EDT - 5 weeks ago

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Jul 17, 2025, 9:15 AM EDT - 4 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelzℱ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Jul 11, 2025, 8:01 AM EDT - 4 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelzℱ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 20, 2025, 7:50 AM EDT - 8 months ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Mar 6, 2025, 8:10 AM EST - 9 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine¼ Procedure using AlloStemℱ

Feb 14, 2025, 7:00 AM EST - 9 months ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine¼ Procedure using AlloStemℱ

Creative Medical Technology Reports Positive One-Year Results for AlloStemℱ Type 2 Diabetes Program

Feb 11, 2025, 9:25 AM EST - 9 months ago

Creative Medical Technology Reports Positive One-Year Results for AlloStemℱ Type 2 Diabetes Program

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Feb 5, 2025, 8:25 AM EST - 10 months ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Jan 30, 2025, 9:25 AM EST - 10 months ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Nov 13, 2024, 9:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Creative Medical Technology Holdings Provides Corporate Update

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelzŸ Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelzŸ Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 7, 2024, 9:15 AM EST - 1 year ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Mar 6, 2024, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Dec 20, 2023, 9:35 AM EST - 2 years ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine¼ using AlloStemℱ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine¼ using AlloStemℱ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine¼ using AlloStemℱ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine¼ using AlloStemℱ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Aug 24, 2023, 10:45 AM EDT - 2 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 14, 2023, 9:00 AM EDT - 2 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 28, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 12, 2023, 8:01 AM EDT - 2 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Creative Medical Technology Holdings Announces Reverse Stock Split

Jun 9, 2023, 12:30 PM EDT - 2 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelzÂź Immunotherapy Platform

May 31, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelzÂź Immunotherapy Platform

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelzÂź Platform Development

May 22, 2023, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelzÂź Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine¼ Procedure Using AlloStemℱ Allogenic Cell Line

May 18, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine¼ Procedure Using AlloStemℱ Allogenic Cell Line

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelzÂź Platform for the Treatment of Brittle Type 1 Diabetes

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelzÂź Platform for the Treatment of Brittle Type 1 Diabetes

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelzÂź Platform Development

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelzÂź Platform Development

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Mar 7, 2023, 8:00 AM EST - 2 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Three Year Follow-Up Results Confirm Efficacy of StemSpineÂź Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 14, 2023, 8:00 AM EST - 2 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpineÂź Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Feb 8, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStemℱ, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStemℱ, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Develops AlloStemℱ Clinical Cell Line

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Develops AlloStemℱ Clinical Cell Line

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpineÂź Study

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpineÂź Study

Creative Medical Technology Announces Positive Top-Line Results for OvaStemÂź Pilot Study

Jul 28, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStemÂź Pilot Study

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelzÂź Immunotherapy Platform

Jun 15, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelzÂź Immunotherapy Platform

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 29, 2022, 8:40 AM EDT - 3 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelzÂź Product

Apr 20, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelzÂź Product

Creative Medical Technology to Showcase CaverStemÂź at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Apr 12, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology to Showcase CaverStemÂź at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Why Creative Medical Technology Shares Are Soaring

Mar 23, 2022, 10:15 AM EDT - 3 years ago

Why Creative Medical Technology Shares Are Soaring

Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

Mar 23, 2022, 10:15 AM EDT - 3 years ago

Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

Creative Medical Technology Announces Positive Top-Line Results for StemSpineÂź Pilot Study

Mar 23, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for StemSpineÂź Pilot Study

Creative Medical Technology to Participate in the 34th Annual Roth Conference

Mar 8, 2022, 8:30 AM EST - 4 years ago

Creative Medical Technology to Participate in the 34th Annual Roth Conference

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Mar 2, 2022, 8:30 AM EST - 4 years ago

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

wokazn
wokazn Nov. 14 at 5:46 AM
$CELZ clue #1🙂 Efficacious in FDA clinical trialđŸ”„ ImmCelzÂź Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients https://share.google/h0CAPW2DsVvsliL8u
1 · Reply
gteu3212
gteu3212 Nov. 11 at 3:22 PM
$CELZ $CELZ đŸ”„â€” Quietly Building a Multi-Billion Dollar Platform đŸ”„ Most traders only see the price. Serious investors look at positioning — and CELZ is positioning itself better than almost any microcap biotech out there. Here’s what the market is missing: ✅ Two FDA-cleared clinical programs running in parallel ✅ Cash runway of ~9M+ after the latest 10-Q ✅ Zero debt ✅ Lowest R&D burn I’ve seen for a company with this pipeline ✅ Early signals of safety + feasibility in ADAPT ✅ Type-1 Diabetes (CREATE-1) could dwarf everything ✅ New BioDefense program = potential access to federal funding ✅ Tiny float → any real news can hit like a bolt of lightning ⚡ When ADAPT delivers in 2026, it won’t just be “good news.” It will be the moment this entire platform becomes validated — and validation is the multiplier nobody is pricing in. Microcaps don’t move gradually. They move all at once
 and usually when people least expect it. #Biotech #CellTherapy #Undervalued
0 · Reply
Peterb3346
Peterb3346 Nov. 11 at 12:30 AM
$CELZ apparently this thing has hiccups. $CELZ can help if you have a stroke, but has problems with hiccups.
0 · Reply
JayGainsby
JayGainsby Nov. 10 at 3:17 PM
$CELZ The recent 10Q gave a good snap shot of CELZ’s warrant landscape and future dilution. Over the next year or two, CELZ’s share count will almost certainly double as the already-paid-for and low-priced warrants convert into stock. This dilution, however, is already priced in and already paid for. Cash today (pro forma) ≈ $9.1 M (Sept 30 balance + Oct net proceeds). If every warrant priced around today’s share level were exercised, CELZ would receive an additional $12 – 13 million in cash and issue about 3.9 million new shares. So, for the next stage of CELZ’s development float will most likely end up around 7.5 M OS with roughly $22 million cash to fund future clinical work. That float is still tiny and the cash runway is great. If science bears out, CELZ has all of the ingredients for huge break out. Bring on the clinical trial updates!
0 · Reply
wokazn
wokazn Nov. 10 at 3:16 PM
$CELZ another piece of the puzzle developing with Greenstone that will benifit Celz's recent BioDefense Inc. news, that was not mentioned. https://www.biopharmadive.com/press-release/20251023-greenstone-biosciences-and-illumina-announce-collaboration-to-advance-preci/
0 · Reply
BoilermakerB
BoilermakerB Nov. 10 at 12:56 PM
$CELZ 10Q out......same old same old, minimal revenue and not profitable yet. Expenses going up and still a long way to topline results on 2 possible products. Also the 10Q disclosed that when the patents are extended, they pay with shares, so dilution is guaranteed to progress as they move toward a actual product..... Long road ahead here....strap in.
2 · Reply
HODLnCaulfield
HODLnCaulfield Nov. 10 at 12:40 PM
$CELZ
0 · Reply
gteu3212
gteu3212 Nov. 10 at 10:46 AM
🚀 $CELZ — The Setup for a Massive 2026 Breakout 🚀 The new 10-Q paints a very clear picture: CELZ is financially stable, burning minimal cash, carrying zero debt, and holding ~$9M+ runway after the recent warrant funding. All clinical programs remain fully intact and moving forward. ✅ ADAPT (lower back pain) now entering the most important stage ✅ CREATE-1 (Type 1 Diabetes) in IND momentum ✅ BioDefense program opening the door to federal funding ✅ Cash burn extremely low for a biotech with TWO FDA-cleared trials ✅ Float still tiny ✅ No toxic financing This is the quiet phase before the storm. Q1/Q2 2026 = the moment we find out if the platform works in humans. If ADAPT hits, the entire ImmCelzℱ engine gets validated
 and that changes everything. 📈 With success: » $10–$18 becomes realistic » $20–$40 on strong efficacy » Multi-program validation = $50+ potential The fundamentals are stronger now than ever before! #CELZFamily #Biotech #RegenerativeMedicine #2026Catalyst
0 · Reply
JayGainsby
JayGainsby Nov. 8 at 12:35 AM
$CELZ Q3 10Q was released. Pros: -~$9.1M cash (~ 20–24 months at the current burn) -Further confirmation that CELZ-201 ADAPT trial looks safe. It’s nearly finished collecting data, and early signs are hopeful, but official results will not be out for a month or two
If efficacy on this treatment holds up (remaining trials/experiments should be affordable with current cash ~) -Lean ops. I'd love to hear about more early bios in stage 1/2 with promising results & $ to cover P3. If efficacy holds up, stock price should recalibrate (and there is a lot more potential in the pipeline/patent umbrella. Positive results/gains in any area would boost ALL of it. Cons OS is increasing. Dilution will likely X2 (at least) in the next ~yr (float will still be TINY & 201 ADAPT should be well on to P3 (or NOT) Warrants’ strike price was reset from 3.75 to $2.86- (not good and the reason for the resetting of the current floor). Clinical trial news remains the KEY factor
0 · Reply
JayGainsby
JayGainsby Nov. 6 at 3:44 PM
$CELZ We should be getting the 3rd Q 10Q shortly (before primary completion clinical trial data) According to Zack's report, "over the last 30 days, the consensus EPS estimate for the current year has increased 32.3%," which indicates some are expecting much better earnings (or losses in this case 🙂) than they predicted earlier. I am interested to see how actual burn/revenue relate to those forecasts and why?
0 · Reply
HODLnCaulfield
HODLnCaulfield Nov. 6 at 2:59 PM
$CELZ after recent warrants were exercised, they’re trading below cash value, correct? About $11M cash , 7m valuation?
1 · Reply
BoilermakerB
BoilermakerB Nov. 5 at 8:40 PM
$CELZ love the newbies now panicking when I told them last week this was going to happen.... Buy the dip and get used to Tims shenanigans
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 5 at 5:02 PM
$CELZ Current Stock Price: $2.80 No options data available.
0 · Reply
ka1954
ka1954 Nov. 4 at 2:38 PM
$CELZ is this company going bankrupt? worse companies have done much higher diilution and didn't see this much killing . this stock is ridiculous
1 · Reply
gteu3212
gteu3212 Nov. 3 at 5:31 PM
$CELZ – The Calm Before The Breakthrough! 🚀 Creative Medical Technology Holdings is quietly setting up for a major move. With the ADAPT trial (lower back pain) entering a crucial phase, we’re now just a few months away from knowing if their ImmCelzℱ regenerative platform truly delivers — and that’s the same tech powering their other upcoming programs (Diabetes, BioDefense, and more). đŸ’„ Think about it: Fully FDA-approved trial underway. Around $10M cash and no major debt. Multiple shots on goal — pain, diabetes, immune & defense applications. If ADAPT confirms efficacy, it validates the entire platform and opens the door to huge partnerships and exponential valuation growth. This company is still flying under the radar
 but not for long. Q1 2026 could be the turning point. Sometimes the best plays are the quiet ones — right before the world catches on. đŸŒŽđŸ”„ $CELZ #Biotech #RegenerativeMedicine #GameChanger
0 · Reply
wokazn
wokazn Nov. 3 at 5:14 PM
$CELZ https://www.nvidia.com/en-us/on-demand/session/gtcdc25-dc51137/
0 · Reply
Peterb3346
Peterb3346 Nov. 3 at 4:23 PM
$CELZ lol @ people who are silly.
0 · Reply
wokazn
wokazn Nov. 3 at 2:28 PM
$CELZ https://www.linkedin.com/posts/timothy-warbington-celz_creative-medical-technology-holdings-inc-activity-7391104400183697408-YAbd?utm_source=share&utm_medium=member_android&rcm=ACoAADG-GcwBtYcdWUyYcGQifsZG7xLS4qRLp3M
0 · Reply
ka1954
ka1954 Oct. 31 at 1:43 PM
$CELZ people if u wanted to sell, why u fucking didn't sell yesterday?
0 · Reply
luxm3
luxm3 Oct. 31 at 6:46 AM
$CELZ ready for pull back 4$...I hope
0 · Reply
ka1954
ka1954 Oct. 30 at 6:57 PM
$CELZ dont understand, why some stocks go down a lot on dilution and others go down and then recover. different category of stocks, there are different traders who are moving the stock. from CELZ volume, i don't even see many traders here, i think it's just retail buying and selling
0 · Reply
StockFlips
StockFlips Oct. 30 at 6:30 PM
$CELZ worth watching
0 · Reply